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Abstract We aimed to investigate the expression of SPARC
(secreted protein, acidic and rich in cysteine) in gastric
cancer and its relationship with tumor angiogenesis and
cancer cells proliferation. Protein expression of SPARC,
VEGF, CD34 and Ki-67 in 80 cases of gastric cancer and
30 cases of normal gastric tissue was evaluated by immu-
nohistochemistry. CD34 staining was used as an indicator of
microvessel density (MVD). Ki-67 labeling Index (LI) indi-
cated cancer cells proliferation. Statistical analysis was used
to investigate its relationship with clinical characteristics,
tumor angiogenesis and cancer cells proliferation. SPARC
expression was mainly in the stromal cells surrounding the
gastric cancer cells, and was statistically significant differ-
ences between gastric cancer and normal gastric tissue (P<
0.05). Both the expression of SPARC and VEGF were
related to differentiation degree, clinical stage, Lauren clas-
sification and lymph node metastasis (P<0.05). Expression
of SPARC was significantly negatively correlated with the
expression of VEGF and MVD in gastric cancer tissues.
Expression of SPARC was also negatively correlated with
Ki-67-LI. Our findings suggest that both the expression of
SPARC and VEGF are closed to tumor angiogenesis in
gastric cancer, SPARC inhibited tumor angiogenesis but
VEGF promoted tumor angiogenesis. SPARC also inhibited
cells proliferation of gastric cancer.
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Introduction
In recent years, although the worldwide incidence of gastric
cancer has decreased, both its incidence and mortality rate
are high in China [1]. The high mortality is closely related to
tumor invasion and metastasis. Angiogenesis plays an im-
portant role in the survival of the malignant cells, in the local
expansion and tumor invasion, as well as in the appearance
of distant metastasis. Angiogenesis is not an active process
by itself, and it is controlled by some angiogenic factors and
some inhibitors of angiogenesis [2]. Of all the angiogenic
factors, vascular endothelial growth factor (VEGF) is a
potent, multifunctional cytokine that exerts several impor-
tant and possibly independent actions on vascular endothe-
lium. That is its property and capacity to induce
angiogenesis, which has excited the greatest interest in
VEGF [3]. Some studies demonstrated that SPARC is relat-
ed to the invasion, metastasis, angiogenesis and growth of
malignant tumor. Other studies found that SPARC could
bind with VEGF and decrease the capability of VEGF
binding with its receptors, and resulted in the inhibintion
of endothelial cell proliferation [4–6].
The purpose of this study was to investigate the relation-
ship between the expression of SPARC with angiogenesis
and cancer cells proliferation, as well as the relationship
with other clinicopathological parameters in gastric cancer.
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Patients and Tissue Speciments
Eighty cases of gastric cancer obtained between January
2008 and April 2009 were identified from our pathol-
ogy files in Department of Pathology at the Fourth
Clinical Hospital of Harbin Medical University, China.
The study group comprised 59 male and 21 female
patients, range 35–83, median age 61. The clinicopath-
ological parameters were obtained from the pathological
reports, including tumor differentiation, lymph node
metastasis, TNM stage and Lauren classification, and
all of these data were reviewed and confirmed by the
experienced pathologists in our department. Thirty
cases of corresponding nontumorous tissue samples
were collected as controls.
Immunohistochemical Staining and Scoring
Sections (4 μm) from the paraffin-embedded, formalin-
fixed gastric cancer tissues were fixed on the charged
slides for immunohistochemical analysis using non-bio-
tin detectionsystem (EliVision. Anti-Mouse/Rabbit-HRP,
DAKO). Primary mouse monoclonal antibodies to
SPARC (clone NCL-O-NECTIN, Novocastra), CD34
(clone QBEnd/10,DAKO Carpinteria, USA), primary
rabbit monoclonal antibodies to VEGF (clone SP28,
Zhongshan) and primary mouse monoclonal antibodies
to Ki-67 (clone SP6, Zhongshan) were used in the
study. All slides were deparaffinized with xylene and
rehydrated through graded concentrations of ethanol
ending with distilled water. Then endogenous peroxidase
was blocked by 0.3% hydrogen peroxide for 10 min.
Sections for SPARC,VEGF, CD34 and Ki-67 for immu-
nohistochemical were subjected to microwave antigen
retrieval with 0.1 M citrate buffer (pH 6.0) at 800 W
for 5 min, and slides were cooled for 20 min at room
temperature and washed in PBS (pH 7.4), then were
i n c u b a t e d1ha t3 7 ° Ci nh u m i d i f i e dc h a m b e r s ,f o l l o w e d
by EliVision detection incubated for 20 min at room
temperature. The staining were visualized by incubating
with 3,3′-diaminob-enzidine for 3~5 min, then counter-
stained with hematoxylin. Sections of known positive
specimens were used as positive controls. Sections in-
c u b a t e dw i t hP B Si n s t e a do fp r i m a r ya n t i b o d yw e r e
used as negative controls.
The intensity of immunostaining for SPARC was reviewed
and scored according to the location of cytoplasmic and
results are presented by two independent observers without
knowledge of the clinicopathological parameters of the
patients. The proportion of cells with SPARC expression
was rated as follows: 0 point, ≤5% positive stromal fibroblast
cells;1 points, 6%~25% positive cells; 2 points , 26%~50%
positive cells; 3 points, ≥51% positive cells. The intensity of
staining varied from weak to strong. The intensity was classi-
fied as a scale of 0(no staining), 1 (weak staining, light
yellow), 2 (moderate staining, yellowish brown), and 3
(strong staining, brown). Staining index was calculated as
the product of staining intensity score and the proportion
of positive stromal cells. We obtained the staining index
with scores of 0,1,2,3,4,6,or 9, a staining index score ≥4
was used to define stromal cells with high SPARC ex-
pression, and a staining index score ≤3 was used to
indicate low SPARC expression [7].
The staining results of VEGF were evaluated by a score
corresponding to the sum between: the percentage of cyto-
plasmic positive tumor cells [8]: 0 point, 0% immunopos-
itive cells; 1 point, ≤25% positive cells; 2 points, 26~50%
positive cells; 3 points, ≥51% positive cells; the staining
intensity: 0 point, negative immunoreaction; 1 point, weak
intensity; 2 points, moderated intensity; 3 points, strong
intensity. The sum of the two parameters varied between 0
and 6: a negative immunoreaction (−) for a score 0~2, and a
positive immunoreaction (+) for a score 3~6.
MVD was assessed according to the criteria proposed by
Weidners et al. [9], the brownish cytoplasmic staining of
vascular endothelial cells was considered positive. The
microvessels were counted according to the number of
single endothelial cell or endothelial cell cluster showing
brownish yellow granules in the cytoplasm. The sections
were observed first under the low-power (×40), then the
most dense area of microvessel sections was selected under
the high-power (×400, the surface area of every vision field
being 0.785 mm
2). The number of microvessels in three
vision fields were counted and averaged as MVD of the
given specimen.
The positive staining of Ki-67 was nuclear staining.
Five areas of highest proliferative activity were selected
randomly at low magnification. Then tumor cell counts
were performed with these areas at a magnification of
×400. 100 tumor cells were counted per field. Ki-67-LI
was defined as the percentage of tumor cell nuclei
staining [10].
Statistical Analysis
SPSS 11.5 was used for the statistical analysis. χ
2 test
was used for testing numeration data and t test was used
to test measurement data. Spearman rank correlation co-
efficient test analysis was performed to examine the
correlations between SPARC and VEGF. Mann–Whitney
U-test was used to assess the association between MVD
with the expression of SPARC and VEGF. We also used
logistic regression analysis. A value of P less than 0.05
was considered statistical significant.
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Expression of SPARC, VEGF, CD34 and Ki-67 in Gastric
Cancer and Normal Gastric Mucosa Tissue (Table 1)
Expression of SPARC protein was detected by immunohis-
tochemistry staining in 80 cases of gastric cancer tissues and
30 cases of corresponding nontumorous tissues. SPARC
was mainly localized in the cytoplasm of stromal cells
surrounding the gastric cancer (Fig. 1a). In this study the
positive expression of SPARC was 61 cases (76.3%) in
gastric cancer, but in normal gastric mucosa tissue it was
only 6 cases (20%). SPARC expression was significant
difference between the positive rate in stromal cells of
gastric cancer and normal gastric mucosa tissue (χ
2010.8,
P00.001).
The positive staining for VEGF was brown granules
in the cytoplasm of gastric cancer cells (Fig. 1b)a n d
normal gastric mucosal epithelial cells. The rate of
positive VEGF expression was 66.3% in gastric cancer
cells and 30% in normal mucosal epithelial cells respec-
tively, with a significant difference between them (χ
20
8.45, P00.004).
MVD any single brown-stained cell or endothelial cell
cluster that marks endothelial cell stained with CD34 was
counted as a single vessel (Fig. 1c).The mean value of MVD
was 43.13±9.88 in tumor tissue, and MVD in tumor cells
nest was significantly higher than that in the normal mucosal
tissue (t08.52, P<0.001).The positive staining for Ki-67
was buffy granules in the nuclei of gastric cancer cells
(Fig. 1d).The mean value of Ki-67-LI was 6.17±1.22 in
normal mucosal epithelial cells, but it was 22.81±7.12 in
gastric cancer cells, the difference was significant (t012.55,
P<0.001).
Relationship of SPARC, VEGF, MVD and Ki-67-LI
with Clinicopathologic Parameters (Table 2)
SPARC expression in stromal cells surrounding the tumor
cells nest was statistically significant difference with differ-
entiation degree, clinical stage, Lauren classification and
lymph node metastasis (P<0.05), but no significant differ-
ence with the patients age, gender, and depth of tumor
invasion. But we found SPARC expression was most closed
to differentiation degree (P00.001) by logistic regression
analysis.
VEGF expression in the gastric cancer cells was sta-
tistically significant difference with differentiation de-
gree, clinical stage, Lauren classification and lymph
node metastasis (P<0.05), but no significant difference
with the patients age, gender, and depth of tumor inva-
sion. We used logistic regression analysis to assess the
relative importance between VEGF and clinicopathologic
parameters, and we found Lauren classification was most
important.
In gastric cancer, MVD was significantly related to
the differentiation degree, clinical stage, depth of tumor
invasion, Lauren classification and lymph node metasta-
sis (P<0.05), but MVD was most related to differenti-
ation degree and clinical stage by logistic regression
analysis.
The mean value of Ki-67-LI in gastric cancer was asso-
ciated with depth of tumor invasion, clinical stage and
lymph node metastasis (P<0.05), but not with differentia-
tion degree, age, gender and Lauren classification. But we
found the clinical stage is the most important by logistic
regression analysis.
Correlation Analysis of SPARC Expression and VEGF
Expression (Table 3)
Using Spearman correlation analysis, SPARC expression in
stromal cells of gastric cancer was negative significantly
related with VEGF expression in cancer cells (r0−0.344,
P00.002).
Correlation Analysis of SPARC and VEGF Expression
with MVD (Table 4)
In gastric cancer with high SPARC expression, the mean
value of MVD was 40.35±8.35, but in the gastric cancer
with low SPARC expression it was 50.15±14.33, with a
significant correlation between them (P00.001). As the
SPARC expression became less and less, the mean value
of MVD gradually increased.
The mean value of MVD was 49.13±12.95 in the posi-
tive VEGF expression tumor tissue, and the mean value of
MVD was significantly higher than that in the negative
VEGF expression tumor tissue (P<0.001).
Correlation Analysis of SPARC Expression and Ki-67-LI
(Table 5)
In eighty cases of gastric cancer, the mean value of Ki-67-LI
was 24.62±8.52 with high SPARC expression, but it was
28.41±8.29 with low SPARC expression. It was significant-
ly different between them (P00.048). As the SPARC
Table 1 Expression of SPARC, VEGF, CD34 and Ki-67 in gastric
cancer and normal gastric mucosa tissue
groups n SPARC VEGF MVD(x  s) Ki-67(x  s)
normal 30 6(20%) 9(30%) 23.16±9.15 6.17±1.22
cancer 80 61(76.3%) 53(66.3%) 43.13±9.88 22.81±7.12
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proliferation gradually increased.
Discussion
Gastric cancer is one of the most common cancer-related
cause of death in China. Most gastric cancer is diagnosed at
stage III or IV, and the rate of lymph node metastasis or
distant metastasis is higher. The invasion and metastasis of
tumor is a multifactorial and multistep process. In this
process, the formation of blood vessels through endothelial
cell proliferation from extant vasculature (angiogenesis) is a
prerequisite [11]. Angiogenesis is regulated by multiple pro-
and anti-angiogenic factors produced by various cell types,
such as cancer, endothelial and stromal cells. The character-
istic of tumor growth is cells proliferation overpass cells
death, at the same time, differentiation is inhibited. Cancer
cells proliferation are caused by genome inreversible
change. In the process of cancer cells proliferation, pro-
and anti-growth gene is essential.
Secreted protein acidic and rich in cysteine (SPARC, also
known as osteonectin or BM-40) belongs to the matricellular
family of secreted proteins [12]. SPARC is a nonstructural
component of extracellular matrices that modulates cell-matrix
interactions, particularly during tissue development, remodeling
and repair [13]. Recent studies have revealed other biological
functions including cell proliferation, migration, deadhesion,
antiproliferation, differentiation, and angiogenesis [14]. Some
studieds demonstrated that SPARC was related with many
Fig. 1 The expression of SPARC, VEGF, CD34 and Ki-67 in gastric
cancer a. High expression of SPARC in stromal cells of intestinal
gastric cancer; b. Strong expression of VEGF in the cytoplasm of
gastric cancer cells; c. Expression of CD34 in endothelial cells of
gastric cancer vessels; d. Ki-67 staining was in the nuclei of gastric
cancer cells
Table 2 Relationship of SPARC , VEGF expression, MVD and Ki-67 with clinicopathologic parameters
SPARC VEGF MVD(x  s) Ki-67(x  s)
parameters n high low P (+) (−) PPP
age
<50 12 7 5 0.531 10 2 0.175 45.33±15.92 0.980 24.76±8.30 0.446
≥50 68 33 35 43 25 45.23±12.12 26.82±8.64
gender
male 59 28 31 0.446 37 22 0.262 45.76±12.44 0.547 27.49±8.48 0.086
female 21 12 9 16 5 43.80±13.42 23.75±8.40
Laurentype
intestinal 38 24 14 0.025 18 20 0.001 38.71±9.21 0.000 25.66±8.90 0.402
diffuse 42 16 36 35 7 51.17±12.50 27.28±8.29
differentiation
high 41 28 13 0.001 21 20 0.004 39.29±9.06 0.000 25.19±8.01 0.157
low 39 12 27 32 7 51.51±12.95 27.91±9.01
stage
I–II 41 26 15 0.014 23 18 0.049 38.76±7.05 0.000 23.86±8.52 0.004
III–IV 39 14 25 30 9 52.08±13.68 29.30±7.79
Tumor
T4 50 24 26 0.644 35 15 0.360 48.98±13.40 0.000 28.52±7.77 0.001
T1-T3 30 16 14 18 12 39.03±8.30 23.16±8.91
LN
N1-N3 48 18 30 0.006 36 12 0.043 49.94±13.70 0.000 28.49±8.29 0.010
N0 32 22 10 17 15 38.22±6.21 23.54±8.23
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Watkins, et al. [15] showed that high levels of SPARC expres-
sionintumorcellsnegativelycorrelatedwiththeoverallsurvival
of patients in breast cancer. However, the increased SPARC
expression in bladder cancer [16] and nonsmall cell lung cancer
[17] indicated a higher malignancy and invasion of tumors with
poor prognosis. N Said, et al. [18] demonstrated that both tumor
and stromal SPARC are limiting for primary prostate tumori-
genesis and progression, through effects on the cell cycle.
To explore if SPARC promotes or inhibits the development
and progression of tumor, we used immunohistochemical
method to detect the expression level of SPARC in human
gastric cancer tissues and their corresponding nontumorous
gastricmucosaincurrentstudy.Theresultsinourstudyshowed
that SPARC expression in stromal cells surrounding gastric
cancer cells nest was significantly higher than that in normal
mucosa tissues. Our results also showed that the high SPARC
expression was statistically significantly different with clinico-
pathological parameters including differentiation degree, clini-
cal stage, Lauren classification and lymph node metastasis. The
results of Siina et al. [19] were similar to that of ours.
Recently, there has been many studies about SPARC
regulating tumor angiogenesis and tumor growth. One study
showed that SPARC peptides have anti-angiogenic activity
in vitro and in vivo. In vivo, SPARC peptides blocked
angiogenesis of neuroblastoma xenografts and inhibited tu-
mor growth [20]. Shanna A et al. [21] utilizing subcutaneous
tumor models demonstrated that pancreatic tumors grown
orthotopically in Sparc-null (Sparc
−/−)m i c ew e r em o r e
metastatic than tumors grown in wild-type (Sparc
+/+) litter-
mates. It also suggested that increased tumor burden in the
absence of host SPARC is a consequence of a disrupted
vascular basement membrane, enhanced vascular function
and an immune-tolerant, pro-metastatic microenvironment.
In our study, we also found that SPARC has the roles of anti-
angiogenesis andantiproliferation.In gastric cancer withlow
SPARC expression, the mean value of MVD and Ki-67-LI
was significantly higher than that of cancer with high
SPARC expression(P<0.05,respectively). Schultz C et al.
[22] also revealed that SPARC may promoteglioma invasion
but delay tumor growth in vitro and in vivo.
VEGF is an Mr 34000-42000 KD, disulfide-linked gly-
coprotein synthesized by several human and animal cell
types, both normal and neoplastic [23]. VEGF target cell is
the endothelial cell. On the other hand, VEGF stimulates the
endothelial cells of microvessels to proliferate, migrate and
alters their pattern of gene expression [24].The high level of
VEGF expression in some malignant tumors predicts high
metastasis risk and poor prognosis, such as ovarian cancer
and non-small cell lung cancer[25, 26]. In current study, we
found that VEGF expression highly correlated to angiogen-
esis, malignancy and metastasis of gastric cancer. The stron-
ger the expression of VEGF, the higher the MVD, the lower
differentiation degree, the higher clinical stage and lymph
node metastasis. These results indicate that VEGF and the
angiogenesis promoted by VEGF play important roles in
cancer growth, infiltration and metastasis in gastric cancer.
Although the mechanism for its anti-angiogenic activity
is not well understood, SPARC is capable of interfering with
the binding of angiogenic stimulators such as VEGF to their
receptors in endothelial cells, resulting in inhibited prolifer-
ation [6]. SPARC has also been shown to down-regulate
VEGF in glioma cells [27]. Similarly, Chlenski et al. [28]
demonstrated that purified SPARC potently inhibited neu-
roblastoma growth and angiogenesis in vivo. This is similar
to our results. In our study, high levels of SPARC in stromal
cells was significantly negative related with VEGF expres-
sion, the mean value of MVD and Ki-67-LI. In addition, our
results revealed that the positive VEGF expression was statis-
tically significantly different with differentiation degree, clin-
ical stage, lymph node metastasis and Lauren classification.
VEGF expression was up-regulated in gastric cancer along
with the decreased expression of SPARC. All of these results
suggest that SPARC may inhibit VEGF expression during the
process of new blood vessel growth by which indirectly
control the development, growth, invasion and metastasis of
tumor cells in gastric cancer.
Table 3 Correlation analysis of SPARC expression and VEGF
expression
VEGF SPARC r P
high low
positive 20 33 −0.334 0.001
negative 20 7
Table 4 Correlation analysis of SPARC and VEGF expression with
MVD
Protein expression MVD(x  s) mean rank ZP
SPARC
high 40.35±8.35 32.04 −3.26 0.001
Low 50.15±14.33 48.96
VEGF
positive 49.13±12.95 48.75 −4.45 <0.001
negative 37.63±7.73 24.31
Table 5 Correlation analysis of SPARC and Ki-67 expression
Protein expression Ki-67(x  s) mean rank ZP
SPARC
high 24.62±8.52 35.36 −1.978 0.048
Low 28.41±8.29 45.64
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In summary, high SPARC expression in stromal cells sur-
rounding the tumor cell nests was related to differentiation
degree, clinical stage, Lauren classification and lymph node
metastasis, and may inhibit the progression of gastric cancer
by anti-angiogenesis and anti-proliferation. The role of anti-
angiogenesis of SPARC may be involved in regulation of
production of angiogenesis factor VEGF. It is believed that
inhibition of SPARC expression is associated with the tumor
progress and invasion process of gastric cancer. Finally, the
regulatory mechanism points to the possibility that SPARC-
targeted gene and protein therapy can be used as a mean-
ingful molecular target therapy of gastric cancer.
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